Clearpoint Neuro Inc

Análisis de la acción Clearpoint Neuro Inc (CLPT)

$15.550

-0.381 (-2.45%)Al cierre

Loading chart…
High
16.080
Open
15.730
VWAP
15.69
Vol
467.84K
Mkt Cap
155.75M
Low
15.442
Amount
7.34M
EV/EBITDA, TTM
-10.03

ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners.

AI analysis of Clearpoint Neuro Inc (CLPT)

hold

ClearPoint Neuro Inc (CLPT) is currently a hold. The stock is priced at $15.55, which is below the analyst price targets ranging from $22 to $30. However, the company is facing significant operational challenges, with a net income loss of $11.3 million in Q2 2026 and a forward P/E ratio of 12.11, indicating potential undervaluation but also underlying financial stress.

Métricas de valoración

The current forward P/E ratio for Clearpoint Neuro Inc (CLPT) is 12.11, compared to its 5-year average forward P/E of -12.78.

Forward P/E

Strongly Overvalued
5Y Average P/E
-12.78
Current P/E
12.11
Sobrevalorada
-2.91
Infravalorada
-22.65

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
-20.27
Current EV/EBITDA
-10.03
Sobrevalorada
-7.74
Infravalorada
-32.81

Forward P/S

Fair
5Y Average P/S
9.11
Current P/S
8.52
Sobrevalorada
13.20
Infravalorada
5.01

Alphio AI Price Scenarios for CLPT

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CLPT

$14.75

Precio del escenario

B

Base

Base · 50%CLPT

$14.47

Precio del escenario

B

Bear

Bear · 25%CLPT

$13.96

Precio del escenario

Cronología de eventos

2026-08-04 (ET)

12:00:00

Major Averages Surge Again, Tech Shares Lead Gains

2026-08-03 (ET)

19:30:00

Stock Futures Broadly Higher, Oil Prices Slip

17:00:00

ClearPoint Neuro Q2 Revenue at $10.88M, Below Consensus

17:00:00

Company Adjusts 2026 Revenue Guidance to $48M - $52M

2026-06-17 (ET)

09:30:00

ClearPoint Neuro Shares Rise 32% to $17.66

Noticias

CLPT FAQ — answered by Alphio AI

ClearPoint Neuro, Inc. is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The Company provides clinical products and preclinical development services for controlled drug and device delivery. Its business consists of two components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. The primary applications for the ClearPoint system are to target and guide the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, and the infusion of pharmaceuticals into the brain. It provides consulting services to its pharmaceutical and other medical technology partners. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

ClearPoint Neuro Inc (CLPT) is currently a hold. The stock is priced at $15.55, which is below the analyst price targets ranging from $22 to $30. However, the company is facing significant operational challenges, with a net income loss of $11.3 million in Q2 2026 and a forward P/E ratio of 12.11, indicating potential undervaluation but also underlying financial stress.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis